Jivi and Rebinyn Will Be New Clotting Factors for Hemophilia

December 2018

New clotting factor products, Jivi (JIH-vee) and Rebinyn (reh-bee-NYNE), will put more focus on hemophilia treatment.

Hemophilia patients have a genetic disorder where clotting factors VIII or IX are missing or don't work correctly. This leads to a high bleeding risk.

Be ready to handle orders for meds to prevent or stop bleeding in patients with hemophilia.

Practical advice for a better career, with unlimited access to CE

Hospital Pharmacy Technician's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Communication Up Your Communication Game With "SBAR"
Migraine Help Migraine Patients Get Needed Meds Right Away
Operations & Management Take Stock of Expiring or Excess Inventory
Antibiotics Think of Eravacycline as Similar to Tigecycline
Biosimilars Clear Up Confusion About Biosimilars
Raynaud's Know How Treatments for Raynaud's Phenomenon Stack Up
Influenza Xofluza Will Be a New Antiviral to Treat the Flu
Hemophilia Jivi and Rebinyn Will Be New Clotting Factors for Hemophilia
Antithrombotics Avoid Errors With the New Strength of Xarelto

Jivi and Rebinyn Will Be New Clotting Factors for Hemophilia

Practical advice for a better career, with unlimited access to CE

Table of Contents